Home › Funds › Atle Fund Management AB › NBIX

Atle Fund Management AB position in NBIX

NEUROCRINE BIOSCIENCES INC · Health Care

Atle Fund Management AB reported holding 38,611 shares of NBIX (NEUROCRINE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$5.5M, representing 1.47% of its reported portfolio and ranking #27 among its reported holdings. Atle Fund Management AB has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)38.61K sh
Reported value held$5.48M
Portfolio Weight1.47%
First reportedQ4 2023
Last changeReduce
Updated2026-11-12

Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR

How Atle Fund Management AB's NBIX position evolved

Atle Fund Management AB first disclosed a stake in NBIX in Q4 2023 at 12,617 shares (US$1.7M). The position peaked in Q4 2025 at 94,796 shares, worth US$13.4M. Across 12 filings, Atle Fund Management AB increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 38,611 shares valued at US$5.5M — a reduction of -34,287 shares quarter over quarter.. Notable position changes include a 245% increase in Q1 2024 (shares were roughly flat over the following quarter), a 156% increase in Q3 2024 (shares rose 18% over the following quarter), a 47% trim in Q3 2026 (shares rose 23% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 12.62K $1.66M New
Q1 2024 43.48K $6.00M Add
Q2 2024 23.63K $3.25M Reduce
Q3 2024 60.61K $6.98M Add
Q4 2024 67.76K $9.29M Add
Q1 2025 75.88K $8.39M Add
Q2 2025 88.39K $11.11M Add
Q3 2025 102.62K $1.53M Add
Q4 2025 94.80K $13.44M Reduce
Q1 2026 89.69K $7.85M Reduce
Q2 2026 72.90K $12.29M Reduce
Q3 2026 38.61K $5.48M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NBIX and 13F data

NBIX (NEUROCRINE BIOSCIENCES INC) is a Health Care company. 34 other funds we track also report a position in NBIX — the largest reported positions include Renaissance Technologies (US$393.7M), Two Sigma Investments (US$349.9M), Vestal Point Capital, LP (US$316.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NBIX

All NBIX fund holders →

FAQ

How long has Atle Fund Management AB held NBIX?

Atle Fund Management AB has disclosed NBIX holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Atle Fund Management AB's current position in NBIX?

As of Q3 2026, Atle Fund Management AB holds 38.61K shares of NBIX (NEUROCRINE BIOSCIENCES INC), valued at $5.48M, representing 1.47% of its reported portfolio and ranking #27.

Has Atle Fund Management AB been buying or selling NBIX?

In the latest 13F filing (Q3 2026), Atle Fund Management AB reduced its position in NBIX. The position peaked in Q4 2025 at 94.80K shares.

Which other funds hold NBIX?

Other major institutional holders of NBIX include Renaissance Technologies, Two Sigma Investments, Vestal Point Capital, LP, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.